With so many biomarkers now guiding gynecologic cancer care, the testing landscape can be difficult to navigate. At the ASCP 2026 Annual Meeting, Gulisa Turashvili will guide learners through the key considerations, towards a more confident approach to biomarker testing and reporting. Here, she previews the learning objectives.
The following transcript has been edited for clarity.
I'm Gulisa Turashvili and I'm an Associate Professor of Pathology at Harvard Medical School and gynecologic and breast pathologist at Mass General Brigham in Boston, Massachusetts, where I also serve as the Subspecialty Director of gynecologic pathology.
Biomarker testing has become central to how we diagnose and manage gynecology cancers. However, in daily practice, choosing the right assay, interpreting the results correctly, and connecting it back to morphology remains a challenge for many pathologists.
This 60-minute session – navigating biomarker testing in gynecologic neoplasms: what, when, and why – takes a practical case-based approach to closing these gaps. The session will examine the key biomarkers relevant to gynecologic pathology including P16 immunohistochemistry and high-risk HPV testing as well as immunohistochemistry for DNA mismatch repair proteins, P-53, hormone receptors, HER2, PDL1, and folate receptor 1. Particular attention will be given to appropriate clinical indications, testing methodologies, interpretation criteria, and recognized pitfalls, as well as current guideline recommendations.
Digital whole slide images from representative cases will be presented throughout the session, paired with polling questions to reinforce key concepts and facilitate engagement of the audience.
By the end of the session, you will be able to list the key prognostic and predictive biomarkers in gynecologic neoplasms, describe the appropriate indication, testing methods, and interpretation categories for each of these biomarkers, discuss the clinical implications of biomarker testing in guiding diagnosis, prognosis, and clinical decision making for patients with gynecologic neoplasms.
So if you work with gynecologic specimens and would like to improve your proficiency with a clearer, more confident approach to biomarker testing and reporting, this session is for you.
Thank you for your attention and hope to see you all in Montréal.
